Close

Natco Pharma wins license to manufacture, sell Nexavar in India

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Fluid Path Integrity: Ensuring Purity in Biomanufacturing

In the high-stakes arena of biomanufacturing, where tiny contaminants...

GMP Fluid Handling: Regulatory Compliance Explained

Fluid Handling in GMP Manufacturing: The Essence of Regulatory...

Single-Use Technologies in Biopharma Transform Manufacturing

The biopharmaceutical sector is being revolutionized by the demand...

Advances in Aseptic fluid transfer solutions

Sterility and Cross-Contamination: The Cornerstones of Modern Biopharma Manufacturing Biopharmaceutical...

The Indian patents office has awarded a license to Natco Pharma to manufacture and sell a generic version of Bayer’s cancer treatment drug Nexavar.

As per the Indian Patents Act, Natco Pharma will be able to make and sell low-cost drug in the country, through a pact with the patent holder, at a price fixed by the Controller General of Patents, Designs and Trademarks. Natco Pharma chief financial officer Baskara Narayana told The Economic Times that sales of the generic version of Nexavar are estimated to be about INR250m ($5m) to INR300m ($6m) every year once it is launched.

Narayana also told NDTV Profit that sale of the drug would earn Natco Pharma 5-10% margins. Under the license, Natco must pay 6% in royalties to Bayer from the sale of the drug, which is needed by about 8,800 cancer patients in India today.

Natco said its version of generic Nexavar would cost Indian patients $175 a month, instead of about $5,600 which Bayer markets sorefinib as Nexavar under a 2008-2020 patent.

Latest stories